Partnering
Grants, Donations and Sponsorships
Geron may provide funding for educational programs and charitable projects that further medical and scientific knowledge that align with our mission to transform the lives of patients with myeloid hematologic malignancies. Requests for funding must be submitted for review. For more information on our charitable giving and eligibility, including required documentation, please refer to a full overview here.
Educational Programs
We provide funding for CME (Continuing Medical Education) and IME (Independent Medical Education) initiatives aimed at improving care and support for people living with Myelodysplastic Syndromes, Myeloproliferative Neoplasms/Myelofibrosis, and Acute Myeloid Leukemia aligned to prioritized content areas as outlined in our Charitable Giving overview.
For CME inquiries, please submit your request here, for IME inquiries, please submit your request here.
Charitable Giving
Philanthropy is a key component of corporate social responsibility. Geron may provide financial support in response to unsolicited requests for charitable funding intended to benefit patients, caregivers, or patient support communities aligned to our prioritized disease areas and content areas. For inquiries, please submit your request here.
If you are unsure which link to select, this form can help.
Business development
With a seasoned leadership team with world-class expertise spanning research, clinical development, regulatory, manufacturing and commercial experience in hematologic malignancies, Geron is prepared to deliver on our mission to change lives by changing the course of blood cancer and other hematological conditions.
We are interested in accelerating value creation through strategic partnerships that have the potential to bring complementary programs, products, and capabilities that would synergize with our first-in-class telomerase inhibitor and further address unmet medical needs globally.
To contact our Business Development team, please send us an email.
Scientific collaborators
Starting with our foundational research, Geron has embraced partnerships that advance the scientific understanding of telomere biology, both in the non-clinical and clinical settings. As part of our pipeline expansion, we are exploring imetelstat’s potential in multiple hematologic malignancies, alone and in combination with current standard of care therapies through early-stage trials.
We invite you to discuss possible collaborations with us that could advance the further development of novel telomerase-based therapies or other possible, innovative approaches to the treatment of hematologic malignancies. For all inquiries, please email us.